logo
Blood test to predict tumor recurrence of advanced skin cancer called highly accurate

Blood test to predict tumor recurrence of advanced skin cancer called highly accurate

Yahoo15-04-2025

ST. PAUL, Minn., April 15 (UPI) -- New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether some stage III melanoma patients are likely to suffer recurrences of cancerous tumors.
The new test looks for a specific type of DNA shed by tumors of stage III melanoma patients who, if found, indicates a strong likelihood their cancer will return in the aftermath of lymph node surgery, according to the authors of a study published Tuesday in The Lancet Oncology.
Stage III melanoma is an advanced form of skin cancer in which the malignancy has spread beyond the original site to nearby lymph nodes or surrounding tissue, requiring aggressive treatment such as surgery, immunotherapy or targeted therapy to restrict its progression.
Using the new test, an analysis of hundreds of blood plasma samples taken from stage III melanoma patients with mutated BRAF genes -- who make up about half of all skin cancer sufferers -- determined that approximately 80% of those who had evidence of circulating tumor DNA, or ctDNA, in their samples eventually went on to develop recurrences of their cancers.
The research was funded by the Swiss pharmaceutical giant Novartis, maker of the melanoma-inhibiting drugs Tafinlar and Mekinist.
The high level of prediction accuracy means oncologists and dermatologists may soon have a valuable new tool to quickly and easily tell which patients are most likely to respond well to follow-on "adjuvant" therapy after surgery, according to Dr. David Polsky, the Alfred W. Kopf Professor of Dermatologic Oncology in the Ronald O. Perelman Department of Dermatology at NYU, as well as an advisory board member for Novartis.
"We think [patients with resected stage III melanoma] would most likely benefit from ctDNA measurements shortly after their surgery -- [for example} within 12 weeks or less as was done in this study -- and periodically thereafter," Polsky told UPI in emailed comments.
Those patients, he said, would for the first time have a "clear, direct measure of the disease itself" -- a significant improvement over the current method of tissue-based analyses of tumor cells that can only suggest the likelihood of recurrence.
Potential benefits
Where the new test could have particularly strong benefits is among melanoma patients who have undergone successful lymph node resections and are currently cancer-free, but who choose to forego follow-up drug therapy due to financial burdens or other reasons. An accurate test for ctDNA could identify which of them are at higher risk and most in need of adjuvant therapy, Polsky said.
"Also, we did have samples from some patients who completed a year of treatment and then stopped their treatment according to the protocol rules," he added. "In some of those patients we detected ctDNA beginning mostly three months after stopping treatment.
"So, another group of patients who might benefit from the test are those patients with resected stage III melanoma who stop their adjuvant therapy and would like to have a blood test to help identify melanoma recurrence should it happen."
Although the test did not detect ctDNA in every patient who eventually recurred, when the test was positive, nearly everybody in that group developed a recurrence detectable on a radiographic scan, Polsky said, adding, "We're hoping that with additional study this test can become part of the routine work-up for patients with melanoma that has escaped the skin and spread to other parts of the body."
Doctors who see a positive ctDNA test result in patients carrying a mutation of the BRAF gene could then take proactive steps, such as ordering a computed tomography, or CT, scan ahead of schedule or requesting a more sensitive PET-CT scan, the authors suggest.
Latest evidence
The study "adds to the increasing evidence that circulating tumor DNA has a useful role in patients where the cancer has been surgically resected and patients are at high risk of recurrence," said Dr. Alastair Greystoke, an oncologist at the Northern Center for Cancer Care in Newcastle-upon-Tyne, England, and an authority on genetic cancer biomarkers. He was not involved in the NYU study.
"[The authors] showed with a robust and relatively cheap blood test that you could predict patients who were likely to relapse following surgery for melanoma that had spread to the lymph nodes, where we hope patients are cured but there is a high chance it will come back," Greystoke told UPI.
"At the moment, these patients are offered extra treatment with targeted drugs or immunotherapy, which reduce the chance of recurrence, but these drugs are expensive can be associated with significant and life changing side-effects and are not needed by all."
Overall, the noted oncologist added, "this study adds to the utility of ctDNA, moving it strongly into the detection and measurement of minimal residual disease to inform decision-making in patients who have had surgery for BRAF-mutated melanoma. It is likely we will see increasing use in this and other tumor types."
Meanwhile, the leader of the world's largest private nonprofit funder of melanoma research told UPI the results of the NYU study are "exciting" and part of a "promising" front in the fight against the disease.
"CtDNA monitoring appears promising to help guide treatment escalation, switching, or de-escalation," said Dr. Marc Hurlbert, CEO of the Melanoma Research Alliance.
Evidence is mounting that keeping an eye on levels of tumor-related genetic material can help in many areas of melanoma treatment, such as identifying patients at high risk of recurrence, monitoring response to treatments, helping to guide treatment selection, signaling "when a switch from an approved agent to a clinical trial might be necessary, and lastly to augment imaging tests for monitoring for disease recurrence," he said.
Hurlbert noted his alliance has funded previous research on analyzing bloodstream biomarkers to detect cancer risk, including an study published this month in which scientists applied low-cost, whole-genome sequencing techniques to ctDNA to identify risks of mutations.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ADHD drugs back in the spotlight after study debunks rising prevalence
ADHD drugs back in the spotlight after study debunks rising prevalence

Yahoo

timea day ago

  • Yahoo

ADHD drugs back in the spotlight after study debunks rising prevalence

An increasing number of patients are seeking support for attention-deficit/hyperactivity disorder (ADHD), with pharmacological-based treatments an important part of medical care for the neurodevelopmental condition. A study published this week in the Journal of Affective Disorders has found that greater awareness and acceptance around the disorder has led to more people seeking help. The research, led by a team at King's College, London, debunks claims that the disorder is 'naturally' on the rise. The data comes as a national taskforce in England investigates what this rising demand for support means for the NHS. Figures published in May 2025 by NHS England estimated there were nearly 2.5 million people in England with ADHD. This includes more than 550,000 currently waiting for an assessment. Every month 20,000 more people are referred for support, a rise of 13% compared to last year. Pharmaceutical Technology looks at some of the current options in the UK and casts an eye ahead to what the future drug landscape might contain. The first choice for patients with ADHD is methylphenidate, which belongs to a class of drugs called central nervous system (CNS) stimulants. The drug, which works by blocking the reuptake of norepinephrine and dopamine, increases activity in the brain, including regions associated with attention and behaviour. It is known under the brand names Ritalin, manufactured by Novartis, and Johnson and Johnson's Concerta. There is also Equasym and Xenidate, among others. Lisdexamfetamine dimesylate is also used to treat patients with ADHD. Like methylphenidate, lisdexamfetamine is a CNS stimulant and acts as a norepinephrine and dopamine reuptake inhibitor (NDRI). This drug is known under the brand name, among others, as Elvanse and Vyvanse, both manufactured by Takeda. While stimulants are fast acting, with side effects felt soon after administration, non-stimulant drugs take longer, yet can offer an alternative if drugs like methylphenidate and lisdexamfetamine dimesylate do not work. While improving, access to pharmacological-based treatments is still impaired amid an ongoing global shortage that began in September 2023. Methylphenidate and lisdexamfetamine were primarily affected – the shortage arising due to a combination of manufacturing issues and increased global demand. A separate study published in The American Journal of Managed Care in March suggested that overdiagnosis of ADHD is fuelling the shortage of stimulation medications. One of the most advanced candidate drugs, and one with notable buzz surrounding it, is Axsome's Sunosi (solriamfetol). Sunosi, which is also an NDRI but not a conventional stimulant, met its primary endpoint in a Phase III trial (NCT05972044) earlier this year. The medication led to a 45% drop in ADHD symptoms. As measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS), 150mg Sunosi dosed achieved average reductions from baseline of 17.7 points, compared to 14.3 points for placebo. Sunosi is already approved in the UK to treat excessive daytime sleepiness (EDS) in adults with narcolepsy, with or without cataplexy. Certain patients with obstructive sleep apnoea (OSA) are also eligible to take the medication. In 2022, Axsome paid $53m up front to acquire Sunosi from Jazz Pharmaceuticals. A drug with a recent approval extension in the US, though not the UK, was Supernus Pharmaceuticals' Qelbree (viloxazine extended-release capsules). The mechanism of action of Qelbree, though unclear, is thought to be through inhibiting the reuptake of norepinephrine. Originally approved for children in 2021, the FDA updated the drug's label in January this year to include adults. ADHD treatments were in the political crosshairs in the US recently. The disorder, along with autism, was singled out by the Trump administration for an 'over-utilisation of medication'. Pharmaceutical intervention remains a helpful part of managing the disorder, though it is part of a combination of treatments that also include coaching and lifestyle changes. "ADHD drugs back in the spotlight after study debunks rising prevalence" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

SpaceX launches 26 Starlink satellites from California amid foggy conditions
SpaceX launches 26 Starlink satellites from California amid foggy conditions

Yahoo

timea day ago

  • Yahoo

SpaceX launches 26 Starlink satellites from California amid foggy conditions

June 8 (UPI) -- SpaceX launched another 26 of its Starlink satellites into low-Earth orbit Sunday amid foggy conditions at Vandenberg Space Force Base in California. The company livestreamed the launch on Elon Musk's X platform, with the footage showing the Falcon 9 rocket obscured by fog before takeoff. SpaceX warned residents in Santa Barbara, San Luis Obispo, and Ventura counties that they might hear "one or more sonic booms" during the launch. After the launch, the first stage booster of the rocket landed on Of Course I Still Love You, a floating barge stationed in the Pacific Ocean. The flight marked the seventh voyage for the first stage booster, which previously launched NROL-126, Transporter-12, SPHEREx, NROL-57, and two Starlink missions.

SpaceX launches 26 Starlink satellites from California amid foggy conditions
SpaceX launches 26 Starlink satellites from California amid foggy conditions

UPI

timea day ago

  • UPI

SpaceX launches 26 Starlink satellites from California amid foggy conditions

SpaceX launched another 26 of its Starlink satellites into low-Earth orbit Sunday amid foggy conditions at Vandenberg Space Force Base in California. Photo courtesy of SpaceX/ X June 8 (UPI) -- SpaceX launched another 26 of its Starlink satellites into low-Earth orbit Sunday amid foggy conditions at Vandenberg Space Force Base in California. The company livestreamed the launch on Elon Musk's X platform, with the footage showing the Falcon 9 rocket obscured by fog before takeoff. Watch Falcon 9 launch 26 @Starlink satellites to orbit from California SpaceX (@SpaceX) June 8, 2025 SpaceX warned residents in Santa Barbara, San Luis Obispo, and Ventura counties that they might hear "one or more sonic booms" during the launch. After the launch, the first stage booster of the rocket landed on Of Course I Still Love You, a floating barge stationed in the Pacific Ocean. The flight marked the seventh voyage for the first stage booster, which previously launched NROL-126, Transporter-12, SPHEREx, NROL-57, and two Starlink missions.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store